Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Macitentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 1.00 |
| ▸ | EDNRB known ✓ | P24530 | 19/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | TSPO | P30536 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Macitentan SCHEMBL29378853 | 1.00 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380505 | 0.94 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL19569175 | 0.94 | EDNRA (0.89) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL19569156 | 0.94 | EDNRA (0.89) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL19569102 | 0.93 | EDNRA (0.88) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380529 | 0.93 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL23876322 | 0.93 | EDNRA (0.86) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380521 | 0.93 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL17582648 | 0.92 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL14380524 | 0.92 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094688-A | Compositions and methods for treating pulmonary arterial hypertension | — | 2026-05-26 | — | — | CN | claimed |
| EP-3810091-B1 | COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION | ABRAXIS BIOSCIENCE LLC (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026089673-A1 | COMPOSITIONS FOR PULMONARY ARTERIAL HYPERTENSION | HUMANIS SAĞLIK A.Ş. (TR) | 2026-04-30 | — | — | WO | claimed |
| US-12577300-B2 | Neutralizing antibodies to human endothelin | Father Flanagan's Boys' Home Business (US) | 2026-03-17 | — | — | US | claimed |
| US-20260069593-A1 | METHODS FOR TREATING CANCER | AMGEN INC (US) | 2026-03-12 | — | — | US | claimed |
| EP-4696689-A1 | SALT FORM AND CRYSTAL FORM OF CHIRAL HETEROCYCLIC COMPOUND HAVING HEDGEHOG PATHWAY ANTAGONIST ACTIVITY | Suzhou Kintor Pharmaceuticals, Inc. (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4691470-A1 | USE OF HETEROCYCLIC COMPOUND IN TREATMENT OF INTERSTITIAL PNEUMONIA | SUZHOU KINTOR PHARMACEUTICALS, INC (CN) | 2026-02-11 | — | — | EP | claimed |
| US-12527839-B2 | Treatments for systemic sclerosis | ACCELERON PHARMA INC. (US) | 2026-01-20 | — | — | US | claimed |
| US-20250367179-A1 | COMPOSITION AND METHODS FOR TREATING HERITABLE PULMONARY ARTERY HYPERTENSION ASSOCIATED WITH NONSENSE MUTATIONS | LUNDQUIST INST FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL CENTER (US) | 2025-12-04 | — | — | US | claimed |
| US-12485119-B2 | Methods of treating pulmonary arterial hypertension | ACTELION PHARMACEUTICALS LTD (CH) | 2025-12-02 | — | — | US | claimed |
| CN-114246871-A | Macetuxintan solid dispersion and preparation method and application thereof | 普济生物科技（台州）有限公司 | 2022-03-29 | — | — | CN | claimed |
| WO-2022051495-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION AND CANCER | ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (US) | 2022-03-10 | — | — | WO | claimed |
| CN-108727279-B | Mmexiteman related substance D, preparation method and application thereof | 南京正大天晴制药有限公司 | 2022-03-08 | — | — | CN | claimed |
| WO-2022045991-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MACITENTAN AND RELEVANT EXCIPIENTS | PHARMACTİVE İLAÇ SANAYİ VE TİCARET A.Ş. (TR) | 2022-03-03 | — | — | WO | claimed |
| CN-114096239-A | Compressed macitentan compositions, methods and uses thereof | 社会医疗技术员技术股份公司 | 2022-02-25 | — | — | CN | claimed |
| EP-3946347-A1 | MACITENTAN FOR USE IN TREATING PORTOPULMONARY HYPERTENSION | Actelion Pharmaceuticals Ltd (CH) | 2022-02-09 | — | — | EP | claimed |
| US-11234980-B2 | Pharmaceutical composition for the treatment of pulmonary arterial hypertension | ACTELION PHARMACEUTICALS LTD (CH) | 2022-02-01 | — | — | US | claimed |
| US-20220024777-A1 | NOVEL AMORPHOUS ACTIVE PHARMACEUTICAL INGREDIENTS COMPRISING SUBSTANTIALLY AMORPHOUS MESOPOROUS MAGNESIUM CARBONATE | DISRUPTIVE PHARMA AB (SE) | 2022-01-27 | — | — | US | claimed |
| EP-3169365-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | Westfälische Wilhelms-Universität Münster (DE) | 2017-05-24 | — | — | EP | claimed |
| WO-2015169884-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2015-11-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069593-A1 | METHODS FOR TREATING CANCER | KRAS, NRAS, HRAS | EDNRA 4211/4885EDNRB 4332/4885SLC6A2 3599/4885 |
| US-12577300-B2 | Neutralizing antibodies to human endothelin | IGLV6-57, ETV1, VEGFA | EDNRA 241/4885EDNRB 220/4885SLC6A2 441/4885 |
| US-11234980-B2 | Pharmaceutical composition for the treatment of pulmonary arterial hypertension | PDE5A, PDE3A, PDE2A | EDNRA 28/4885EDNRB 65/4885SLC6A2 1608/4885 |
| US-20250367179-A1 | COMPOSITION AND METHODS FOR TREATING HERITABLE PULMONARY ARTERY HYPERTENSION ASSOCIATED WITH NONSENSE MUTATIONS | BMPR2, BMP1, BMPR1B | EDNRA 41/4885EDNRB 19/4885SLC6A2 1211/4885 |
| US-12527839-B2 | Treatments for systemic sclerosis | TGFBR2, TGFBR1, SMAD2 | EDNRA 92/4885EDNRB 48/4885SLC6A2 625/4885 |
| US-12485119-B2 | Methods of treating pulmonary arterial hypertension | EDNRB, EDNRA, PDE5A | EDNRA 2/4885EDNRB 1/4885SLC6A2 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.